VIENNA, December 2021: For the first time in the history of the company, Biome Diagnostics has been mentioned in the FInancial Times. (https://www.ft.com/content/3546b07e-d865-46d2-8130-328d3eb82e6e).
Generally, Austria is growing as a very attractive city for entrepreneurs, and has already set itself on the map as an innovation hub for many start-ups.
Kit Gillet has shared his thoughts in an article in Financial Times highlighting what Austria has to offer for start-ups. He also focuses on the community of entrepreneurial women that supports and empowers females. Of course, he has taken the testimony of our co-founder Barbara Sladek!
We are also part of the increasingly long list of young companies that decided to start their activity in Austria, now a recognised meeting point for innovators and entrepreneurs!
BiomeOne describes the current efforts of BiomeDx towards the world’s first stool-based response prediction test for immunotherapy (ICI). Currently, the biomarker is tested in three tumor types: non-small-cell lung cancer, renal cell carcinoma and malignant melanoma. Early research efforts support the idea of a tumor agnostic biomarker that can be used for any tumor type. Read more on BiomeOne.
Biome Diagnostics GmbH (BiomeDx) is world leader in microbiome diagnostic products for oncology. The Austrian based MedTech company is committed to advance precision medicine by pioneering microbiome-based technologies that transform cancer care. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice. It is the world first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.